Table 7.
Pairwise meta-analysis of VEGFR-TKIs’ serious hypertension (grade 3 or higher)
| Direct compare | Study Number | Total Sample | Odds Ratio (95% CI) | Method | Heterogeneity |
|---|---|---|---|---|---|
| Cabozantinib vs placebo | 2 | 1027 | 17.02 (5.34,54.26) | M–H random | I2 = 0% (P = 0.52) |
| Suntinib vs placebo | 4 | 1282 | 8.82 (3.43,22.70) | M–H random | I2 = 0% (P = 0.61) |
| Sorafenib vs placebo | 9 | 4732 | 5.20 (3.22,8.39) | M–H random | I2 = 0% (P = 0.74) |
| Regorafenib vs placebo | 6 | 2050 | 4.42 (2.29,8.54) | M–H random | I2 = 38% (P = 0.15) |
| Vandetanib vs placebo | 4 | 1474 | 4.22 (1.74,10.23) | M–H random | I2 = 0% (P = 0.49) |
| Nintedanib vs placebo | 2 | 848 | 5.99 (1.91,18.78) | M–H random | I2 = 0% (P = 0.89) |
| Pazopanib vs placebo | 5 | 2038 | 6.89 (4.72, 10.04) | M–H random | I2 = 0% (P = 0.91) |
| Axitinib vs sorafenib | 2 | 999 | 3.87 (0.36,41.97) | M–H random | I2 = 82% (P = 0.02) |
| Nintedanib vs sorafenib | 2 | 188 | 1.90 (0.30,11.92) | M–H random | I2 = 0% (P = 0.88) |